Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Study of Multiparametric Renal MRI for CKD Progression (AFiRM).

Kidney international reports·2026
Same author

Hexokinase controls platelet activation and hemostasis.

Platelets·2026
Same author

Prevalence and incidence of left ventricular systolic dysfunction and adverse outcomes in patients receiving <i>de novo</i> and replacement pacemaker therapy for bradycardia.

European heart journal open·2026
Same author

The impact of calorific screening thresholds and weight status when validating UK supermarket transaction records in dietary evaluation: FIO-STRIDE.

International journal of obesity (2005)·2026
Same author

Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes.

JACC. Basic to translational science·2026
Same author

Exercise Capacity and the Force Frequency Relationship in Multi-Point Versus Single-Point Pacing: A Randomized Trial.

Pacing and clinical electrophysiology : PACE·2026
Same journal

Incidence and Clinical Predictors of Cognitive Decline in Anticoagulated Patients with Atrial Fibrillation. The Strat-AF Study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation - insights from acute and chronic electroanatomic remapping in the randomized SINGLE-SHOT CHAMPION trial.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Pulmonary vein reconnection patterns after pentaspline pulsed field ablation for atrial fibrillation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Angioplasty for Pulmonary Vein Stenosis after Atrial Fibrillation Ablation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Atrial cardiomyopathy as a multidomain disease: longitudinal evidence for autonomic remodelling.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction.

John Gierula1, Richard M Cubbon, Haqeel A Jamil

  • 1Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics, Health and Therapeutics, Multidisciplinary Cardiovascular Research Centre, University of Leeds, Clarendon Way, Leeds LS2 9JT, UK.

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
|June 6, 2013
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy (CRT) significantly improves heart function and quality of life in pacemaker patients with left ventricular systolic dysfunction (LVSD) and right ventricular (RV) pacing. This intervention, performed during pulse generator replacement (PGR), offers substantial benefits over standard pacing.

Keywords:
Heart failureLeft ventricular dysfunctionPacemaker

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: May 10, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Permanent pacemakers often lead to left ventricular (LV) systolic dysfunction (LVSD) due to unavoidable right ventricular (RV) pacing.
  • Existing treatments for heart failure in these patients are limited, especially when severe symptoms are absent.

Purpose of the Study:

  • To evaluate the efficacy of cardiac resynchronization therapy (CRT) during pulse generator replacement (PGR) in patients with RV pacing and LVSD.
  • To assess if CRT improves cardiac function and clinical outcomes in this specific patient population.

Main Methods:

  • A randomized controlled trial involving 50 patients with unavoidable RV pacing and LVSD undergoing PGR.
  • Patients were randomized to either standard RV-PGR or CRT.
  • Primary endpoint: change in LV ejection fraction (LVEF) at 6 months; secondary endpoints included exercise capacity, quality of life, and NT-proBNP levels.

Main Results:

  • CRT significantly improved LVEF by 9% compared to a decrease of -1.5% in the RV-PGR group (P < 0.0001).
  • CRT also led to improvements in peak oxygen consumption (P = 0.007), quality of life (P = 0.03), and NT-proBNP levels (P = 0.007).
  • Long-term follow-up showed fewer hospitalizations in the CRT group, and two patients in the RV-PGR arm required CRT for worsening heart failure.

Conclusions:

  • Performing CRT during PGR in pacemaker patients with RV pacing and LVSD, even without severe symptoms, enhances cardiac function.
  • CRT improves exercise capacity, quality of life, and reduces NT-proBNP levels in this patient cohort.
  • This strategy offers a significant clinical benefit for patients with pacemaker-induced LVSD.